Investors Are Encouraged to Join the ADMA Biologics Securities Fraud Class Action Lawsuit

Investors Mobilize for Action Against ADMA Biologics

In a significant development for shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA), a national firm dedicated to shareholder rights, Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against the company over allegations of securities fraud. The lawsuit specifically targets violations outlined in the Securities Exchange Act of 1934, particularly focusing on sections 10(b) and 20(a), along with Rule 10b-5 enforced by the U.S. Securities and Exchange Commission.

Timeline and Eligibility

The class period for the lawsuit spans from August 9, 2024, to March 25, 2026. Shareholders who acquired ADMA shares during this timeframe are urged to reach out to SBS for consideration as potential lead plaintiffs in the ongoing legal proceedings. It's crucial to emphasize that individuals do not need to be appointed as lead plaintiffs to benefit from any possible recovery.

Allegations Against ADMA

According to court documents, the allegations detail that ADMA made numerous false and misleading statements that misrepresented the company's financial status. Notably, they engaged in undisclosed related party transactions and utilized questionable practices like channel stuffing to artificially inflate revenue figures. Furthermore, the company purportedly failed to maintain adequate internal control mechanisms, leading to a series of misstatements about its financial health.

As more details emerged, it became clear that the truth surrounding ADMA’s operations was obscured from the public, resulting in significant financial losses for investors once the misleading information was finally disclosed.

Next Steps for Shareholders

Shareholders who believe they have suffered losses due to these alleged maneuvers are strongly encouraged to join the case. SBS is offering consultations free of charge to discuss the implications of the securities fraud allegations and how shareholders might address their losses.

Those interested can contact Brian Schall or David Schwartz directly at SBS’s office located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or via telephone at 310-301-3335. Alternatively, inquiries can also be submitted through the firm's official website or through email at [email protected].

Know Your Rights

It is important for affected shareholders to be aware that the class in this lawsuit has not yet received certification. Until that process completes, individuals are not officially represented by an attorney. Therefore, shareholders can choose to remain passive as absent members of the class or actively participate in pursuing a resolution for their grievances.

Experience and Advocacy

Schall, Brown & Schwartz LLP prides itself on its commitment to representing investors globally. The firm’s partners bring extensive skills and knowledge to the table, as they specialize in securities class action lawsuits and shareholder rights litigation. Their dedication to protecting investor rights and advocating for fair treatment in the marketplace is well-documented.

Ultimately, for those who invested in ADMA Biologics and are struggling with losses, this class action represents an opportunity for recovery and accountability. With the deadline for participating set for August 10, 2026, time is of the essence to protect your investments.